Evidence before
the glow.
Independent, evidence-led reviews of GLP-1s, peptides, metabolic pipeline therapies, hormones, skincare, and procedures — with source notes, caveats, and clinician questions before hype.
Retatrutide: triple-agonist watch
New calculator + deep guide for the phase 2 signal, with investigational status kept front and center.
“The oral GLP-1 watchlist: what pill convenience does and does not solve.”
in glow.
GHK-Cu copper peptide: the skin-repair peptide, audited.
A deep, source-backed guide to GHK-Cu / copper tripeptide-1: what it is, why skincare and peptide clinics talk about it, what human evidence exists, where the gene-expression story gets overhyped, and how to think about topical vs injectable use.
Retatrutide: the triple-agonist obesity drug everyone is watching.
A deep, source-backed guide to retatrutide, the investigational GLP-1/GIP/glucagon triple agonist, including phase 2 weight-loss data, diabetes results, liver-fat signals, safety questions, and why access hype is premature.
Sermorelin peptide therapy: what the evidence can actually support.
A deep, source-backed guide to sermorelin, growth-hormone signaling, FDA history, longevity-clinic claims, safety questions, and where the anti-aging pitch outruns human outcomes data.
Primary GLP-1 Guides
Core guides for approved medications, safety questions, nutrition, and maintenance.
Beginner GLP-1 Guide
Start with the plain-English overview of semaglutide, tirzepatide, access, safety, and maintenance.
Semaglutide
Evidence, labels, side effects, and tradeoffs for Wegovy and Ozempic.
Tirzepatide
What the evidence and Zepbound label support after the hype.
Side Effects
Common, serious, and red-flag symptoms worth discussing with a clinician.
Compounded GLP-1s
Understand FDA concerns, sourcing questions, and why approved-product data cannot be copy-pasted.
Nutrition on GLP-1s
Protein, hydration, fiber, and muscle retention while appetite drops.
Maintenance After GLP-1
Plan for plateaus, protein, strength, dose changes, coverage shifts, and stopping conversations.
Decision Tools
Education-only calculators and question builders for cleaner clinician conversations.
Decision Suite
Five interactive tools for therapy comparison, cost, safety, nutrition, and timelines.
Retatrutide Calculator
Estimate the phase 2 retatrutide average weight-change signal with investigational caveats.
Therapy Match
Fit questions to narrow the therapy conversation with a clinician.
Cost Estimator
Insurance and cash-pay planning scenarios, not price predictions.
Safety Explorer
Label warnings and clinician prompts side by side.
Nutrition Planner
Protein and fiber targets as conversation starters.
Timeline Simulator
Milestones, not personal predictions.
Doctor Questions
Bring a structured checklist to the clinician conversation instead of a TikTok protocol.
Pipeline + Adjacent Therapies
Trending metabolic, peptide, liver, and next-generation therapy topics — clearly labeled.
Next-Gen Pipeline
Track retatrutide, CagriSema, amycretin, oral GLP-1s, and metabolic-liver crossover therapies without access hype.
Oral GLP-1 Medicines
Understand orforglipron, oral semaglutide, pill convenience, and evidence gaps.
Amylin + CagriSema
The next satiety pathway to understand — cagrilintide, amycretin, and combination research.
Ultimate Peptide Guide
What peptides are, why they are popular, what evidence supports them, and which safety questions matter.
Peptide Comparison Table
Claims, evidence, and safety questions compared side by side.
Trust + Editorial
Source trails, methodology, roadmap, and ways to send corrections or tips.
Research Library
Every evidence note, indexed with evidence labels and review dates.
Medical Sources
Review the FDA, NIH, MedlinePlus, PubMed, and trial links behind the site's claims.
How We Research
Evidence grades, source hierarchy, and caveats behind every article.
Editorial Standards
Corrections, disclosures, conflict policies, and the medical-advice boundary.
Glossary
Plain-English definitions for treatments, mechanisms, and evidence labels.
The Cover Review
May 2026 · 12 min read
Retatrutide vs. tirzepatide: evidence, mechanism, and status compared.
A source-led comparison of the investigational triple agonist retatrutide and the FDA-approved dual agonist tirzepatide, with trial maturity, outcomes, safety caveats, and availability kept separate from hype.
The Index
Reviewed source notes · dated updates
GHK-Cu copper peptide: the skin-repair peptide, audited.
A deep, source-backed guide to GHK-Cu / copper tripeptide-1: what it is, why skincare and peptide clinics talk about it, what human evidence exists, where the gene-expression story gets overhyped, and how to think about topical vs injectable use.
Retatrutide: the triple-agonist obesity drug everyone is watching.
A deep, source-backed guide to retatrutide, the investigational GLP-1/GIP/glucagon triple agonist, including phase 2 weight-loss data, diabetes results, liver-fat signals, safety questions, and why access hype is premature.
Sermorelin peptide therapy: what the evidence can actually support.
A deep, source-backed guide to sermorelin, growth-hormone signaling, FDA history, longevity-clinic claims, safety questions, and where the anti-aging pitch outruns human outcomes data.
NAD+, NR, NMN, and IV NAD therapy: where the science ends and the hype begins.
A deep guide to NAD+ biology, oral precursors, IV drips, supplement claims, clinical evidence, safety questions, and why raising a biomarker is not the same as reversing aging.
What to ask your clinician before starting a GLP-1 medicine.
A practical, source-backed checklist for discussing semaglutide, tirzepatide, compounded products, monitoring, side effects, pregnancy planning, cost, and long-term maintenance without turning the visit into an internet protocol.
Retatrutide and “anti-aging” peptides: what the evidence can actually support.
A source-backed review of a viral retatrutide, GHK-Cu, and MOTS-c video: where the biology is plausible, where human data exists, and where the claims outrun the evidence.
Orforglipron and the oral GLP-1 watchlist.
Why a daily pill could change the GLP-1 market — and why convenience still does not answer efficacy, safety, access, and maintenance questions.
Amycretin, CagriSema, and the amylin moment.
The next metabolic medicine story may be less about one receptor and more about multi-pathway satiety signals.
The maintenance plan after GLP-1 weight loss.
Plateaus, protein, resistance training, coverage loss, dose changes, and the question everyone postpones: what happens if you stop?
The MASH-obesity crossover: mazdutide, pemvidutide, survodutide.
Why metabolic therapy is spilling into liver disease headlines, and how to avoid mixing up weight-loss, liver-fat, and MASH endpoints.
Tirzepatide, after the hype.
The uncomfortable parts of the GLP-1 boom that rarely make it into glossy before-and-afters: tolerance, muscle retention, cost, access, and what happens when treatment stops.
Semaglutide vs. Tirzepatide: a 36-week head-to-head.
Mean BMI loss, lean-mass preservation, lipid panels and the side-effect curve nobody charts honestly.
Epitalon: the longevity peptide that won't quit the headlines.
Old research, modern protocols, and why telomere language can sound more settled than the evidence actually is.
Polynucleotide salmon DNA injectables, audited.
What early dermatology data and patient photos suggest: texture looks more plausible than lift, and the word “regenerative” needs a haircut.
The case for early HRT — and the studies that quietly buried the WHI.
Timing, symptom burden, bone density, risk stratification, and why menopause medicine still argues with a 2002 headline.
The Glow Index
Evidence labels · not treatment rankings